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Summary
Esophageal neuroendocrine neoplasms (E-NENs) are much rarer than other gastro-
entero-pancreatic neuroendocrine neoplasms, the majority showing aggressive behav-
ior with early dissemination and poor prognosis. Among E-NENs, exceptionally rare well 
differentiated neuroendocrine tumors (E-NET) and more frequent esophageal poorly dif-
ferentiated neuroendocrine carcinomas (E-NEC) and mixed neuroendocrine-non neuro-
endocrine neoplasms (MiNEN) can be recognized. E-NECs usually exhibit a small cell 
morphology or mixed small and large cells. Esophageal MiNEN are composed of NEC 
component admixed with adenocarcinoma or squamous cell carcinoma. Gastric (G) NENs 
encompass a wide spectrum of entities ranging from indolent G-NETs to highly aggres-
sive G-NECs and MiNENs. Among G-NETs, ECL-cell NETs are the most common and, 
although composed of histamine-producing cells, are a heterogeneous group of neoplastic 
proliferations showing different clinical and prognostic features depending on the patient’s 
clinico-pathological background including the morphology of the peri-tumoral mucosa, 
gastrin serum levels, presence or absence of antral G-cell hyperplasia, and presence or 
absence of MEN1 syndrome. In general, NET associated with hypergastrinemia show a 
better outcome than NET not associated with hypergastrinemia. G-NECs and MiNENs are 
aggressive neoplasms more frequently observed in males and associated with a dismal 
prognosis. 
Key words: neuroendocrine neoplasms, neuroendocrine tumor, neuroendocrine 
carcinoma, MiNEN, stomach, esophagus
NeuroeNdocriNe Neoplasms of the esophagus
Introduction 
Esophageal neuroendocrine neoplasms (E-NENs) are much rarer than 
other gastro-entero-pancreatic neuroendocrine tumors accounting for 
only 0.04-1%. More than 4000 cases have been described in the inter-
national literature 1, where E-NENs represent 0.03-0.05% of all esoph-
ageal malignancies 2-4. Their incidence has been increased in the last 
decades, probably as a secondary effect of improvement in diagnosis 
and clinician awareness. The majority of E-NENs show an aggressive 
behavior with early dissemination and poor prognosis depending on size 
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and grade. Unfortunately, the rarity of this neoplasm 
has not yet permitted the prospective recruitment of 
patients in clinical trials, in order to establish biological 
features and the optimal therapeutic regimen. 
Clinical presentation 
Mean age of E-NEN patients at diagnosis is 66 years 
with a male prevalence (6:1 ratio). More than 50% 
of cases originate in the lower third of the esopha-
gus  5. Only a small fraction of patients with E-NEN 
are asymptomatic and incidentally discovered during 
endoscopy, while most patients present with dyspha-
gia and weight loss. Less frequent symptoms are pain, 
hoarseness, and bleeding1. Given the frequent high 
grade of these neoplasms, carcinoid syndrome is 
extremely rare, while paraneoplastic syndromes are 
slightly more frequent. 
Less than 1% of E-NENs are well differentiated, while 
the great majority are high grade poorly differentiated 
small cell neuroendocrine carcinomas, which present 
with common lymph node and distant metastases 
(31-90% of cases) 1,6. Distant metastases are usually 
located in the liver, lung and bone, while brain metas-
tases are relatively rare7.
Prognostic factors are unclear because of the rarity 
of this neoplasm and the scarcity of collected data in 
international literature. Age, disease extent, TNM clas-
sification and type of treatment (local +/- systemic) are 
the main prognostic factors affecting survival. 
E-NENs treatment is dependent on histological sub-
type, grade and stage, but the most effective thera-
peutic algorithm has not been established. Guidelines 
suggest, in analogy with lung small cell neuroendo-
crine carcinoma, similar therapeutic protocols includ-
ing chemotherapy, radiotherapy and surgery  7. Re-
cently, a retrospective study analyzing 250 stage I-III 
E-NEN patients, suggests that patients treated with 
surgical resection plus chemo and/or radiotherapy 
show a better 2 year survival than patients without 
surgical resection of the primary tumour  8. Radical 
surgery alone provides limited benefits. Neuroendo-
crine carcinoma of the esophagus has a worse prog-
nosis in comparison to esophageal adenocarcinoma 
and squamous cell carcinoma 5. 
Histological features 
defiNitioN aNd termiNology
E-NENs are defined as epithelial neoplasms with pre-
dominant neuroendocrine differentiation 7. In this cat-
egory the following are included: esophageal well dif-
ferentiated neuroendocrine tumors (E-NET), esopha-
geal poorly differentiated neuroendocrine carcinomas 
(E-NEC), and mixed neuroendocrine-non neuroendo-
crine neoplasms (MiNEN).
E-NETs (grade 1 to 3) are extremely rare; mitotic and 
Ki67 cut off values for grading are analogous to those 
applied in other sites. More than 90% of E-NENs are 
represented by small cell NECs, while a minority by 
large cell NECs. In a recent case series of 69 consec-
utive MiNENs, the esophagus and gastro-esophageal 
junction was identified as the second commonest site 
of origin (15.9% of cases) after colon-rectum 9. Among 
MiNEN, the most frequently reported type is the Mixed 
AdenoNeuroendocrine carcinoma (MANEC). 
microscopic descriptioN 
E-NETs are characterized by a proliferation of uniform, 
medium sized cells with abundant cytoplasm, ovoid 
nuclei with dispersed ‘salt and pepper’ chromatin and 
inconspicuous nucleoli, growing in insular, trabecular 
or cribriform pattern with interposed well-vascularized 
stroma.
E-NECs are more frequently of the small cell subtype 
composed of small round, ovoid or spindle-like cells 
with hyperchromatic nuclei with dense chromatin or-
ganized in ample solid insulae or festoons, with multi-
focal necrosis and frequent mitoses (Fig. 1). A relative-
ly small proportion of E-NECs are composed of large 
cells with basophilic cytoplasm and marked nuclear 
atypia with prominent nucleoli. 
MiNEN are usually composed of NEC admixed with 
an adenocarcinoma or squamous cell carcinoma (with 
the two components histologically and immunohisto-
chemically distinguishable). Less than 10 cases of Mi-
NEN composed of NEC and squamous cell carcino-
ma of the esophagus are reported in the international 
literature as case reports 10-11. 
Immunohistochemical and molecular 
markers 
Synaptophysin, chromogranin A, and CD56 immuno-
histochemical stains are used to demonstrate neu-
roendocrine differentiation and positivity for these 
markers varies between 60% and 100% of cases with 
chromogranin A expression usually focal and/or faint 
in E-NECs.
Hormones can be expressed by neoplastic cells in-
cluding serotonin, glucagon and gastrin, but in gen-
eral in NET.
Alcian blu-PAS and cytocheratin 7 can be used to 
demonstrate and quantify the adenocarcinomatous 
component in MiNEN, while p63, p40 and cytokeratin 
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5/6 are used to confirm the squamous component.
No significant data on molecular biology of these tu-
mors is available.
Differential diagnosis 
The main differential diagnosis for E-NENs, in particu-
lar E-NECs, is with metastases from lung small cell 
NEC. Clinical history and imaging are of particular ef-
fort in this setting, since transcription factor immuno-
histochemistry is not useful.
Importantly, MiNENs have to been distinguished from 
carcinoma with focal neuroendocrine differentiation 
applying two main diagnostic criteria: the recognition 
of structural features of neuroendocrine morphology 
(i.e. organoid or solid growth pattern) and the exten-
sion of each component (at least 30%).
NeuroeNdocriNe Neoplasms of the stomach
Introduction 
NENs of the stomach include small indolent NETs 
and highly aggressive NECs. They account for about 
4% of all NENs with an estimated annual incidence 
of 0.4 cases/100,000 persons in both USA and Eu-
rope 12-13. Rare MiNENs are also observed.
gastric NeuroeNdocriNe tumors (Nets)
ECL-cell NETs
Most gastric NETs are composed of ECL-cells and 
are located in the corpus-fundus (oxyntic) mucosa 
(Tab. I). They are commonly separated into three dif-
ferent clinical-pathological subtypes with prognostic-
Figure 1. (A) Esophageal small cell neuroendocrine carcinoma undermining normal squamous esophageal mucosa; H&E, 
magnification 4x. (B) Small cell neuroendocrine carcinoma infiltrating the muscular wall of the esophagus; H&E, magnifi-
cation 10x. (C) Diffuse positivity of neoplastic cells for synaptophysin, magnification 20x. (D) Faint, dot-like, positivity for 
Chromogranin A; magnification 20x. (E) High proliferative index, 80% (Ki-67 stain), magnification 20x.
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significance, gastrin-dependent type 1 and type 2 of 
proven ECL-cell nature and gastrin independent type 
3 of less obvious cell type characterization 14-17.
All gastric NETs are graded into three proliferative 
grades, according to WHO 2019 correlating with prog-
nosis 16-17. The best prognostic stratification of patients 
is obtained by coupling the above clinico-pathological 
classification and the WHO tumor proliferative grade 18.
All gastric NETs are characterized by the expression 
of chromogranin A, synaptophysin and somatostatin 
receptor type 2A. ECL-cell NETs are also positive for 
VMAT2 and histidine decarboxylase (HDC). A few 
scattered cells may be immunoreactive for serotonin, 
ghrelin, somatostatin, and alpha-hCG. 
Type 1 
Type 1 ECL-cell NETs are the most common type, 
arise in a background of autoimmune chronic atrophic 
gastritis associated with reduction/lack of acid secre-
tion and consequent antral G-cells hyperplasia and 
hypergastrinemia. Patients are often female and may 
have autoantibodies against intrinsic factor and/or pa-
rietal cells. Due to the impaired absorption of vitamin 
B12, a sub-group of patients may also present macro-
cytic anemia.
Tumors are generally multiple, small (< 1 cm), limited 
to the mucosa or submucosa and located in the cor-
pus-fundus. Only larger tumors (> 1 cm) may infiltrate 
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the muscularis propria or beyond. They are composed 
of well-differentiated cells with monomorphic nuclei, in-
conspicuous nucleoli, and fairly abundant eosinophilic 
cytoplasm, arranged in small microlobular and/or tra-
becular structures (Fig. 2A). Mitotic activity is absent 
or low and necrosis is lacking. Most cases are G1, but 
G2 and exceptional G3 cases have been described 17. 
The surrounding oxyntic mucosa is atrophic, showing 
ECL-cell hyperplasia and dysplasia (Fig. 2A-B). In the 
antral mucosa G-cells hyperplasia is the rule.
Patients with type 1 ECL-cell NETs have an excellent 
prognosis with a 10-year survival rate of more than 
90%. No significant difference for patient outcome 
was found between G1 and G2 cases, suggesting tu-
mor grade may not be the most important predictor in 
this subgroup 17. The risk for lymph node metastasis 
correlates with tumor size and deep wall invasion 17.
Type 2
Type 2 ECL-cell NETs account for about 5-7% of ECL-
cell NETs and are observed in patients with MEN1 
syndrome, without gender predilection. Tumors are 
generally multiple, measure < 2 cm and arise in hy-
pertrophic-hypersecretory oxyntic mucosa due to gas-
trin stimulation. Hyperplastic and dysplastic ECL-cell 
proliferations are observed in the hypertrophic peritu-
moral mucosa. Hypergastrinemia is caused by a du-
odenal or, more rarely, a pancreatic gastrinoma. Pa-
tients with sporadic gastrinomas do not develop ECL-
cell NETs 19, suggesting the MEN1 defect is required 
for ECL-cell transformation upon gastrin stimulus 20.
Type 3
Type 3 NETs were traditionally considered ECL-cell 
NETs. However, since histamine production or typical 
“ECL-type” secretory granules were not demonstrat-
Figure 2. Type 1 ECL-cell NET is composed of well-differentiated cells arranged in small microlobular and/or trabecular 
structures (A, bottom). The peritumoral oxyntic mucosa (A, top) is atrophic with diffuse intestinal metaplasia and shows ECL-
cell linear and micronodular hyperplasia, easily detected with chromogranin A immunostaining (B). Type 3 NETs is composed 
of well differentiated neuroendocrine cells as well, deeply invading the gastric wall (C, right). Peritumoral oxyntic mucosa is 
normal (C, left) without ECL-cell proliferations (D).
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ed in all cases, the designation ECL-cell has been re-
moved in the last WHO classification 21. Type 3 NETs 
account for about 10-15% of gastric NETs and are 
more frequent in males than in females. Patients do not 
associate with hypergastrinemia and/or chronic auto-
immune atrophic gastritis and may present symptoms 
related to tumor growth or metastatic dissemination.
Type 3 NETs are solitary and large lesions composed 
of well differentiated neuroendocrine cells frequently 
invading the muscularis propria and the sub-serosa 
(Fig. 2C). Lymph node and distant metastases are not 
rare. Most cases are G1 or G2, but G3 NETs were 
described  16. The diagnosis on small biopsy may be 
a challenge and is achieved by evaluating the peritu-
moral mucosa which is usually normal or with minimal 
gastritis (Fig. 2C-D).
The prognosis of type 3 NETs depends on grade and 
stage with a 10-year disease-specific survival of about 
50% 16-17.
Provisional types
Two additional types have recently been proposed, 
which are worth being considered while awaiting full 
clinico-pathologic and/or biochemical characteriza-
tion.
Provisional Type 4 ECL-cell NETs were described in 
association with achlorhydria, parietal cell hyperpla-
sia and hypergastrinemia. The gastric mucosa shows 
dilated oxyntic glands with inspissated secretory lumi-
nal material and parietal cells with often vacuolated 
abundant eosinophilic cytoplasm 22-23. The pathogen-
esis was linked to inappropriate acid secretion from 
functional defective parietal cells with mutated gas-
tric proton pump α-subunit, antral-G cell hyperplasia 
and hypergastrinemia. Only two cases were carefully 
documented, one of which with lymph node metasta-
ses 23.
Provisional Type 5 ECL-cell NETs arising in moderate 
hypergastrinemic patients treated continuously for a 
long time (at least one year) with PPI, without auto-
immune chronic atrophic gastritis, gastrinoma, and 
MEN1 syndrome have recently been described  24. 
Since these tumors are associated with a normal or 
slightly hyperplastic peri-tumoral oxyntic mucosa, 
they may mimic in part type 3 NETs, from which they 
need to be differentiated due to the different progno-
sis  25. Indeed, this ECL-cell NET subtype shows a 
better behavior that type 3 NET not requiring an ag-
gressive surgical approach. Tumors are slightly more 
frequent in males. Lymph node metastases have been 
described in about 15% of patients, but prognosis is 
excellent.
Commentary on provisional types: a report on a famil-
ial cluster of classical Type 1 ECL-cell tumors demon-
strated a high incidence of mutation of the ATP4A 
proton pump gene 26. Although this heritable condition 
defined a specific clinical profile (younger age of on-
set, higher malignancy and iron deficiency anemia), 
it represents a proof of concept that gastrin depend-
ent ECL-cell NETs may result from the combination 
of both epigenetic and predisposing genetic factors, 
either known (MEN1 syndrome genetic changes) or 
presently unknown. This possibility requires careful 
investigation, especially concerning provisional types.
Other gastric NETs
G-cell, D-cell, and EC-cell NETs are rare (about 5% 
of all gastric NENs) and usually non-functioning. Gas-
trin-producing G-cell NETs are generally small, locat-
ed in proximity of the pylorus and are composed of 
well-differentiated neuroendocrine cells forming thin 
trabeculae or gyriform structures. Neoplastic cells are 
positive for neuroendocrine markers, somatostatin 
receptor (subtype 2A), and gastrin. Somatostatin-pro-
ducing D-cell NETs are extremely rare and located in 
the antrum. They are composed of well-differentiated 
monomorphic cells positive for chromogranin A, syn-
aptophysin and somatostatin. In general, both G-cell 
and D-cell NETs are indolent with excellent prognosis, 
even in the presence of deep wall invasion or lymph 
node metastasis  13. EC-cell NETs may arise in any 
part of the stomach and are composed of well-differ-
entiated cells with intense eosinophilic cytoplasm in 
nests with a peripheral palisading. Tumor cells are 
positive for general neuroendocrine markers, seroto-
nin, CDX2, and somatostatin receptor subtype 2A.
gastric NeuroeNdocriNe carciNoma (Nec)
Gastric NECs account for about 6-21% of gastric 
NENs and usually arise in the antral or cardial regions. 
Males are more frequently affected (male/female ra-
tio of 2:1) with 65 years (range 41-76 years). Patients 
generally present non-specific symptoms due to lo-
cal growth or metastatic dissemination. Usually large 
lesions, gastric NECs are small and large cell types 
at histology. Neoplastic cells are positive for synap-
tophysin while chromogranin A is either faint or ex-
pressed with a peripheral or para-nuclear dot-like pat-
tern. NECs may also express nuclear TTF1 or CDX2. 
Patients’ prognosis is dismal prognosis with survival 
usually measured in months.
gastric mixed NeuroeNdocriNe-NoN NeuroeNdocriNe 
Neoplasm (miNeN)
MiNEN are usually large, polypoid, ulcerating or sten-
otic lesions. The neuroendocrine component is often a 
NEC (small or large cell subtypes) and only rarely a 
NET. The non-neuroendocrine component is generally 
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an adenocarcinoma or, rarely, a squamous cell carci-
noma especially when in the cardial region. MiNENs 
composed by adenocarcinoma and NEC (MANEC) ac-
count for about 20% of all digestive MiNENs 27. Patients 
have a poor prognosis and the Ki67 proliferative index 
of the NEC component correlates with prognosis 27. 
Rare cases of adenoma associated with NET have al-
so been reported 28.
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